Pregnancy. Sequelae of complication of pregnancy, childbirth and the puerperium
Conditions
Interventions
Intervention 1: Intervention group 1: Multivitamin-mineral supplements containing 5000 IU vitamin A, 15 IU vitamin E, 400 IU vitamin D3, 1.5 mg vitamin B1, 1.7 mg vitamin B2, 20 mg niacin, 2 mg vitami
Sponsors
Kashan University Of Medical Science
Eligibility
Sex/Gender
Female
Age
18 Years to 35 Years
Inclusion criteria
Inclusion criteria: Pregnant women primigravida Aged 18-35 year old who were carrying singleton pregnancy at their second and third trimester
Exclusion criteria
Exclusion criteria: Multiparous women Patients with hypertension Gestational diabetes mellitus (GDM) Complete bed rest (CBR) Intra uterine fetal death (IUFD) Placenta abruption Preterm delivery Intrauterine growth restriction (IUGR) History of rheumatoid arthritis, thyroid, parathyroid or adrenal diseases Hepatic or renal failure Hospitalization Signs of malabsorption and maldigestion Metabolic bone disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HDL. Timepoint: Baseline and end-of-trial. Method of measurement: Enzymatic kit.;Iron. Timepoint: Baseline and end-of-trial. Method of measurement: Enzymatic kit.;Total glutathione. Timepoint: Baseline and end-of-trial. Method of measurement: Spectrophotometry.;Insulin. Timepoint: Baseline and end-of-trial. Method of measurement: Elisa kit.;Newborns' weight. Timepoint: Delivery time. Method of measurement: Scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Calcium. Timepoint: Baseline and end-of-trial. Method of measurement: Enzymatic kit.;Vitamin D. Timepoint: Baseline and end-of-trial. Method of measurement: Elisa kit.;Magnesium. Timepoint: Baseline and end-of-trial. Method of measurement: Enzymatic kit.;Zinc. Timepoint: Baseline and end-of-trial. Method of measurement: Enzymatic kit.;Total antioxidant. Timepoint: Baseline and end-of-trial. Method of measurement: Spectrophotometry.;Newborn's head circumference. Timepoint: The first 24 h after birth. Method of measurement: Tape.;Newborn's length. Timepoint: The first 24 h after birth. Method of measurement: Tape.;Apgar score. Timepoint: Delivery time. Method of measurement: Clinical observation.;Triglycerides. Timepoint: Baseline and end-of-trial. Method of measurement: Enzymatic kit.;Cholesterol. Timepoint: Baseline and end-of-trial. Method of measurement: Enzymatic kit.;Insulin resistance. Timepoint: Baseline and end-of-trial. Method of measurement: Using HOMA formula.;VLDL. Timepoint: Baseline and end-of-trial. Method of measurement: Enzymatic kit.;LDL. Timepoint: Baseline and end-of-trial. Method of measurement: Enzymatic kit.;Hs-CRP. Timepoint: Baseline and end-of-trial. Method of measurement: Elisa kit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZatollah Asemi
Kashan University of Medical Sciences
Outcome results
None listed